MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX)

152 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q2 2024.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 60.7M shares of 63.5M outstanding shares and own 95.54% of the company stock.
Largest 10 shareholders include BVF INC/IL (21.8M shares), Cormorant Asset Management, LP (8.49M shares), FMR LLC (3.64M shares), Avoro Capital Advisors LLC (2.77M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.56M shares), CITADEL ADVISORS LLC (2.27M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.83M shares), Holocene Advisors, LP (1.63M shares), GOLDMAN SACHS GROUP INC (1.25M shares), and FEDERATED HERMES, INC. (1.13M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.